TG Therapeutics Inc is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases. The company's approved products in the US include Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. The pipeline products of the company include TG-1701 and TG-1801 for the treatment of B-cell cancers and other diseases. The company also evaluates products and technologies for in-licensing, partnership, acquisition, and investment.

TG Therapeutics, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

Hercules Capital

#Milestones – TG Therapeutics announced preliminary 4th quarter and full year 2023 net BRIUMVI revenue (unaudited), as well as our anticipated development milestones for 2024! Read the press release here: bit.ly/4aNu3nd #FearlessForPatients #TGTX #Strategy2024

#DontMissIt – TG CEO Mike Weiss will be presenting at the 42nd Annual J.P.Morgan Healthcare Conference in 15 minutes! Live Webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

#DontMissIt – TG CEO Mike Weiss will be presenting today at the 42nd Annual J.P.Morgan Healthcare Conference - Tues, Jan. 9th @ 4:30PM PT/7:30PM ET. Live Webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

#Breaking - Just announced a Global License Agreement with Precision BioSciences for the Development & Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases. Details: bit.ly/3vzHEhG #FearlessForPatients #TGTX

#SaveTheDate - TG CEO Mike Weiss will present at the 42nd Annual J.P.Morgan Healthcare Conference next week. Live webcast Tues, Jan. 9th @ 4:30PM PT/7:30PM ET. Details: bit.ly/47qzxS7 webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

The team at TG Therapeutics wishes you and your family a very happy and healthy holiday season! #TGTX #FearlessForPatients

#Today - Join the Fireside Chat with TG's CEO Mike Weiss during the 6th Annual Evercore ISI HealthCONx Conference at 2:10PM ET today. Webcast at: https://lnkd.in/eguXMYM #TGTX #EvercoreISI #FearlessForPatients

#SaveTheDate Join our CEO Mike Weiss for a Fireside Chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th at 2:10PM ET. Webcast at: https://lnkd.in/eguXMYM #TGTX #EvercoreISI #FearlessForPatients

#Reminder – Don’t miss today’s Fireside chat with TG’s CEO Mike Weiss at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference. Webcast today, Nov. 6th at 3:10PM ET at https://lnkd.in/eC6nRGS #TGTX #GuggenheimSecurities #FearlessForPatients

#DontMissIt – Join the Fireside Chat with TG CEO Mike Weiss at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference. Webcast on Mon., Nov. 6 at 3:10PM ET at https://lnkd.in/eC6nRGS #TGTX #GuggenheimSecurities #FearlessForPatients

COM:TGTHERAPEUTICS

TG Therapeutics Inc

Last Close

27.90

08/11 21:00

Market Cap

3.17B

Beta: -

Volume Today

3.34M

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

peer of

Metrics